Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Curis (NASDAQ:CRIS) announced its quarterly earnings data on Monday. The biotechnology company reported ($1.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.11, Zacks reports. The firm had revenue of $2.70 million for the quarter, compared to analyst estimates of $2.04 million. Curis had a negative net margin of 443.35% and a negative return on equity of 923.37%.

Curis Price Performance

Shares of NASDAQ CRIS opened at $1.46 on Wednesday. The stock has a market capitalization of $12.36 million, a price-to-earnings ratio of -0.19 and a beta of 3.49. The firm’s 50 day simple moving average is $2.97 and its 200-day simple moving average is $3.83. Curis has a 12 month low of $1.40 and a 12 month high of $17.49.

Analysts Set New Price Targets

A number of brokerages have commented on CRIS. StockNews.com began coverage on Curis in a research report on Saturday. They set a “hold” rating for the company. HC Wainwright decreased their target price on Curis from $20.00 to $16.00 and set a “buy” rating for the company in a report on Monday.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.